The research specifically extracted mentions of common and rare cutaneous ADRs (eg, rashes, blisters, and psoriasis flares) from posts related to (1) the epidermal growth factor receptor inhibitor, erlotinib, and (2) the immune checkpoint programmed cell death–1 inhibitors, nivolumab and pembrolizumab. The gene discussed is EGFR; the disease is psoriasis.